Ultragenyx Pharmaceutical (RARE) Return on Invested Capital (2018 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Return on Invested Capital of 0.04% for Q1 2026, up 6.0% year-over-year from 0.03% in Q1 2025, and down 76.5% on a QoQ basis from 0.15% in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 9 years of Return on Invested Capital data on file, last reported at 0.04% in Q1 2026.
- Quarterly Return on Invested Capital rose 6.0% year-over-year to 0.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.04% (up 6.0% YoY) and the FY2025 annual result came in at 0.06%, down 3.0% from the prior year.
- Return on Invested Capital slipped to 0.04% in Q1 2026 per RARE's latest filing, from 0.15% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.15% in Q4 2025 and bottomed at 0.09% in Q3 2025.
- The 5-year median for Return on Invested Capital is 0.02% (2025), against an average of 0.02%.
- Peak annual rise in Return on Invested Capital reached 18 bps in 2025, while the deepest fall reached 8 bps in 2025.
- Tracing RARE's Return on Invested Capital over 5 years: stood at 0.02% in 2022, then tumbled by 131 bps to 0.04% in 2023, then increased by 16 bps to 0.03% in 2024, then surged by 588 bps to 0.15% in 2025, then tumbled by 77 bps to 0.04% in 2026.
- Per Business Quant, the three latest RARE Return on Invested Capital figures stand at 0.04% (Q1 2026), 0.15% (Q4 2025), and 0.09% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -0.01% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -0.01% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.01% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | 0.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.04% |
| Dec 31, 2025 | 0.15% |
| Sep 30, 2025 | -0.09% |
| Jun 30, 2025 | -0.03% |
| Mar 31, 2025 | -0.02% |
| Dec 31, 2024 | -0.03% |
| Sep 30, 2024 | -0.01% |
| Jun 30, 2024 | -0.02% |
| Mar 31, 2024 | -0.03% |
| Dec 31, 2023 | -0.04% |
| Sep 30, 2023 | -0.07% |
| Jun 30, 2023 | -0.04% |
| Mar 31, 2023 | -0.02% |
| Dec 31, 2022 | -0.02% |
| Sep 30, 2022 | -0.01% |
| Jun 30, 2022 | -0.01% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | 0.00% |
| Jun 30, 2021 | 0.00% |
| Mar 31, 2021 | 0.00% |
| Dec 31, 2020 | 0.00% |
| Sep 30, 2020 | 0.00% |
| Jun 30, 2020 | -0.01% |
| Mar 31, 2020 | -0.01% |
| Dec 31, 2019 | -0.01% |
| Sep 30, 2019 | -0.01% |
| Jun 30, 2019 | 0.00% |
| Mar 31, 2019 | -0.01% |
| Dec 31, 2018 | -0.01% |
| Sep 30, 2018 | -0.01% |
| Jun 30, 2018 | -0.01% |
| Mar 31, 2018 | -0.01% |